Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80210
Name primary mediastinal B-cell lymphoma
Definition A diffuse large B-cell lymphoma that is is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma diffuse large B-cell lymphoma primary mediastinal B-cell lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02393157 Phase II Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) Recruiting USA 0
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT03049449 Phase I ATLCAR.CD30 cells Cyclophosphamide + Fludarabine T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Completed USA 0
NCT03103971 Phase I Cyclophosphamide + Fludarabine + HuJCAR014 huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Terminated USA 0
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Terminated USA 0
NCT03287817 Phase Ib/II Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) Completed USA | GBR 0
NCT03356054 Phase Ib/II Brentuximab vedotin + Cisplatin + Cytarabine + Dexamethasone + Rituximab Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL) Recruiting NLD 0
NCT03610724 Phase II Tisagenlecleucel Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 4
NCT03625037 Phase Ib/II Epcoritamab-bysp First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 6
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting USA 0
NCT03743246 Phase Ib/II Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) Completed USA | NLD | ITA | FRA | ESP | DEU 0
NCT03744676 Phase II Lisocabtagene maraleucel A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Completed USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT04007029 Phase I Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting USA 0
NCT04088864 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies Active, not recruiting USA 0
NCT04088890 Phase I Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies Active, not recruiting USA 0
NCT04160195 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma Terminated USA 0
NCT04161248 Phase I Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Recruiting CAN 0
NCT04205838 Phase II Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma Recruiting USA 0
NCT04231747 Phase I CC-97540 A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Completed USA | CAN 0
NCT04231877 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma Suspended USA 0
NCT04257578 Phase Ib/II Acalabrutinib + axicabtagene ciloleucel Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Recruiting USA 0
NCT04314843 Phase Ib/II axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) Terminated USA 0
NCT04531046 Phase II axicabtagene ciloleucel Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation Active, not recruiting FRA | BEL 0
NCT04535102 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab POLA+BR for Relapsed or Refractory DLBCL Withdrawn 0
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04608487 Phase I Cyclophosphamide + Fludarabine axicabtagene ciloleucel Axi-cel in CNS Lymphoma Active, not recruiting USA 0
NCT04665765 Phase II Polatuzumab vedotin-piiq Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting USA 0
NCT04703686 Phase II Glofitamab-gxbm + Obinutuzumab Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy Active, not recruiting FRA 0
NCT04745949 Phase II Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC) Recruiting USA 0
NCT04759586 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Recruiting USA | CAN | AUS 1
NCT04833114 Phase III Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE) Recruiting GBR | ESP | DEU | AUT 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Active, not recruiting FRA | BEL 0
NCT04844866 Phase II Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) Recruiting NLD | ITA | FRA | ESP | DEU | BEL | AUT 5
NCT04875195 Phase II Pembrolizumab A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Active, not recruiting USA | ITA | FRA | CAN 7
NCT04882163 Phase Ib/II Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma Withdrawn USA | GBR | FRA | ESP | BEL | AUT 2
NCT04889716 Phase II Glofitamab-gxbm + Obinutuzumab Mosunetuzumab-axgb CAR-T Followed by Bispecific Antibodies Recruiting USA 0
NCT04975555 Phase II Siltuximab Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Recruiting USA 0
NCT05005442 Phase II MK-7684A A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN 10
NCT05020015 Phase II iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Active, not recruiting USA 0
NCT05025800 Phase Ib/II Evorpacept + Lenalidomide + Rituximab ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT05065866 Phase I Azacitidine + Duvelisib Duvelisib in Combination With CC-486 in Lymphoid Malignancy Active, not recruiting USA 0
NCT05077527 Phase I axicabtagene ciloleucel Cyclophosphamide + Fludarabine Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Not yet recruiting USA 0
NCT05098613 Phase I CD19/CD22 CAR T cells Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients Recruiting USA 0
NCT05202782 Phase II Zanubrutinib Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Recruiting USA 0
NCT05255601 Phase Ib/II Nivolumab + Relatlimab A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 0
NCT05260957 Phase II Mosunetuzumab-axgb + Polatuzumab vedotin-piiq CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Recruiting USA 0
NCT05270057 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) Recruiting USA 0
NCT05359211 Phase I NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05459571 Phase II axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) Active, not recruiting USA 0
NCT05464719 Phase II Loncastuximab tesirine-lpyl A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Recruiting USA 0
NCT05507541 Phase II Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT05533775 Phase Ib/II Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) Recruiting USA | ITA | FRA | ESP | DEU | AUS 2
NCT05588440 Phase Ib/II Cyclophosphamide + Fludarabine ONCT-808 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting USA 0
NCT05607420 Phase Ib/II Alemtuzumab UCART20X22 Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) Recruiting USA | FRA | ESP 0
NCT05633615 Phase II Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT05641428 Phase II axicabtagene ciloleucel ARI-0001 Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) Recruiting NLD 0
NCT05664217 Phase II NKTR-255 NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma Recruiting USA 0
NCT05672251 Phase II Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT05702853 Phase Ib/II CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Recruiting USA 0
NCT05757700 Phase I 19(T2)28z1xx TRAC CAR-T cells Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma Recruiting USA 0
NCT05773040 Phase I JV-213 A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas Active, not recruiting USA 0
NCT05794958 Phase I axicabtagene ciloleucel Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Recruiting USA 0
NCT05820841 Phase III Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED) Recruiting DEU 0
NCT05821088 Phase II Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Tafasitamab-cxix Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Recruiting USA 0
NCT05826535 Phase Ib/II IMPT-314 Study of IMPT-314 in R/R Aggressive B-cell Recruiting USA 0
NCT05878184 Phase I Cyclophosphamide + Fludarabine SC291 Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) Recruiting USA | AUS 0
NCT05879744 Phase I CLN-978 A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Active, not recruiting USA 0
NCT05929716 Phase II Hu5F9-G4 + Rituximab An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Withdrawn 0
NCT05934448 Phase II Pembrolizumab Pembro Plus CAR T-cell Therapy in R/R in PMBCL Recruiting USA 0
NCT05950165 Phase Ib/II CHO-H01 A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma Recruiting USA 1
NCT05950334 Phase I Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) Recruiting USA 0
NCT05989204 Phase I HuCART19-IL18 TmCD19-IL18 in CD19+ Cancers Recruiting USA 0
NCT06014762 Phase I P-CD19CD20-ALLO1 P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies Recruiting USA 0
NCT06088654 Phase Ib/II IPH6501 Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma Recruiting USA | AUS 0
NCT06173518 Phase I Obecabtagene autoleucel A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) Recruiting GBR 0
NCT06208735 Phase I CLIC-2201 CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Not yet recruiting CAN 0
NCT06238648 Phase II Epcoritamab-bysp Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Not yet recruiting USA 0
NCT06242834 Phase II Pembrolizumab + Tazemetostat Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Not yet recruiting USA 0
NCT06271057 Phase II CC-99282 Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse Not yet recruiting FRA 0
NCT06285422 Phase I Cyclophosphamide + Fludarabine SC262 Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) Recruiting USA 0
NCT06290622 Phase I INCAGN02385 + INCAGN02390 + Retifanlimab PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Not yet recruiting USA 0